American Journal of Health-System Pharmacy最新文献

{"title":"Complexities of evidence-based medicine: Challenges for practice and policy development.","authors":"Brian W Gilbert, Brittany D Bissell Turpin","doi":"10.1093/ajhp/zxae253","DOIUrl":"10.1093/ajhp/zxae253","url":null,"abstract":"","PeriodicalId":7577,"journal":{"name":"American Journal of Health-System Pharmacy","volume":" ","pages":"359-363"},"PeriodicalIF":2.1,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142124558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insomnia in ambulatory care: A clinical review.","authors":"Julie A Dopheide, Winter R Roth, Michelle K L Chu","doi":"10.1093/ajhp/zxae255","DOIUrl":"10.1093/ajhp/zxae255","url":null,"abstract":"<p><strong>Purpose: </strong>One-third to one-half of ambulatory care patients report insomnia. The objective of this clinical review is to detail the many causes and evidence-based treatment options for insomnia in outpatients and to recommend screening and summarize evidence for the place in therapy of prescription and nonprescription treatments.</p><p><strong>Summary: </strong>This work provides an overview of the literature on insomnia regarding causes, patient assessment, and nonpharmacological and pharmacological treatments. Patients who present with insomnia should be assessed for sleep apnea, restless legs syndrome, narcolepsy, and all contributing medications as well as medical, psychiatric, and substance use disorder diagnoses. The type of insomnia, namely difficulty falling asleep, difficulty maintaining sleep, and early morning awakening with resulting functional impairment, should be documented in addition to whether insomnia is short term or persistent. Cognitive behavioral therapy for insomnia (CBT-I) or digital CBT-I is first-line treatment for all patients with insomnia irrespective of the cause or type. Nonprescription treatments such as antihistamines or melatonin are for select populations. Prescription hypnotics are best utilized on an as-needed basis or for nightly use for less than 6 weeks. Z-hypnotics are safe and effective for insomnia in persons with depression or an anxiety disorder but should be avoided in older individuals or if there is respiratory or cognitive impairment. Orexin receptor antagonists are effective for sleep initiation and maintenance in healthy persons or if there is mild cognitive impairment, but they require further study in individuals with psychiatric and medical diagnoses. Trazodone is the most prescribed off-label treatment due to its efficacy for sleep initiation and maintenance and its lack of abuse potential.</p><p><strong>Conclusion: </strong>Insomnia treatment should be guided by patient age, diagnoses, and type of insomnia. Pharmacological treatments should be used at the lowest effective dose for the shortest duration of time.</p>","PeriodicalId":7577,"journal":{"name":"American Journal of Health-System Pharmacy","volume":" ","pages":"265-284"},"PeriodicalIF":2.1,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142339293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying disruptive papers in pharmacy literature that changed clinical practice: 1954-2014.","authors":"Adan Z Becerra, Leslie Kam, Yoona Kim, Haesuk Park","doi":"10.1093/ajhp/zxae309","DOIUrl":"10.1093/ajhp/zxae309","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to identify research publications that have significantly influenced clinical practice in pharmacy using a novel metric known as the disruption score.</p><p><strong>Methods: </strong>We conducted a bibliometric analysis and PubMed search of pharmacy practice articles published in 11 key pharmacy journals and articles tagged with the MeSH term \"pharmacy\" or \"pharmacist.\" Utilizing a validated dataset of disruption scores encompassing articles published between 1954 and 2014, we identified the top 100 most disruptive papers alongside the top 100 most cited papers. Additionally, we explored comparisons between these lists and across various journals to gain comprehensive insights into the field's evolution over time.</p><p><strong>Results: </strong>A total of 59,535 articles met the inclusion criteria, of which 56,764 (95%) were published in the 11 core pharmacy practice journals we chose while 2,771 (5%) were published in other PubMed-indexed journals. Notably, the top 100 most disruptive papers were deemed more disruptive than 99.9% of the entire PubMed universe. The most cited paper was the 22nd most disruptive paper. The mean citation count among the top 100 most disruptive papers was 196. The 1990s was the most disruptive decade, and American Journal of Health-System Pharmacy was the most disruptive journal. We observed a weak correlation between disruption score and citation count.</p><p><strong>Conclusion: </strong>The disruption score identified an innovative body of landmark papers whose legacy will remain solidified in pharmacy practice. The disruption score offers a unique perspective on clinical significance, complementing other bibliometric indices and adding to the identification of papers that have introduced new paradigms in pharmacy.</p>","PeriodicalId":7577,"journal":{"name":"American Journal of Health-System Pharmacy","volume":" ","pages":"317-340"},"PeriodicalIF":2.1,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142492889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent and anticipated novel drug approvals (4Q 2024 through 3Q 2025).","authors":"Matthew H Rim, Collin Dean, Enela Aliaj, Matthew Dandino, Tara Tanriverdi, Andrew M Levitsky","doi":"10.1093/ajhp/zxae352","DOIUrl":"10.1093/ajhp/zxae352","url":null,"abstract":"<p><strong>Purpose: </strong>Health-system pharmacists play a crucial role in monitoring the pharmaceutical pipeline to manage formularies, allocate resources, and optimize clinical programs for new therapies. This article aims to support pharmacists by providing updates on new and anticipated novel drug approvals.</p><p><strong>Summary: </strong>Selected drug approvals anticipated in the 12-month period covering the fourth quarter of 2024 through the third quarter of 2025 are reviewed. The analysis emphasizes drugs expected to have significant clinical and financial impact in hospitals and clinics, as selected from among 51 novel drugs awaiting US Food and Drug Administration approval. New drugs for severe rare diseases, cancers, autoimmune diseases, acute pain, and reversal of anticoagulation are being developed. Additionally, a new cell therapy for treatment of graft-versus-host disease joined the group of novel targeted therapies for various diseases awaiting approval.</p><p><strong>Conclusion: </strong>Novel therapies for treating rare diseases and cancers continue to strengthen the current drug pipeline.</p>","PeriodicalId":7577,"journal":{"name":"American Journal of Health-System Pharmacy","volume":" ","pages":"291-296"},"PeriodicalIF":2.1,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142692590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of change in regulations on buprenorphine prescribing for opioid use disorder.","authors":"Evon Ibrahim, Kaitlyn DeHoff, Eric Lambart, Molly Bray, Mary Marogi","doi":"10.1093/ajhp/zxaf035","DOIUrl":"https://doi.org/10.1093/ajhp/zxaf035","url":null,"abstract":"<p><strong>Disclaimer: </strong>In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.</p><p><strong>Purpose: </strong>In December 2022, federal regulations in the US changed to increase access to buprenorphine for patients who need treatment for opioid use disorder (OUD), removing the requirement for prescribers to obtain a DATA waiver. This study's purpose was to evaluate the impact of these changes in regulations on buprenorphine prescribing for OUD at a community teaching hospital.</p><p><strong>Methods: </strong>This single-center, retrospective cohort study investigated buprenorphine prescribing habits before and after the requirement for a DATA waiver was removed. The study focused on patients who had a diagnosis code for OUD or had buprenorphine with or without naloxone ordered for OUD from March 1 to December 20, 2022 (before the changes) and from March 1 to December 20, 2023 (after the changes). The primary outcome was the percentage of patients with OUD who received buprenorphine with or without naloxone before and after the changes in regulations.</p><p><strong>Results: </strong>Of the 386 patients for whom charts were reviewed, 162 patients met the inclusion criteria: 81 patients in the before group and 81 patients in the after group. Before the changes in regulations, 40% of patients with OUD had buprenorphine ordered in the inpatient setting, compared to 63% of patients after regulations were changed (P = 0.003). More patients had their home buprenorphine regimen continued in the inpatient setting in the after group than in the before group (53% vs 37%; P = 0.04).</p><p><strong>Conclusion: </strong>After removal of the DATA waiver requirement for buprenorphine prescribing, more patients with OUD were prescribed buprenorphine during hospitalization and at discharge​.</p>","PeriodicalId":7577,"journal":{"name":"American Journal of Health-System Pharmacy","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of paralytic choice on postintubation sedation and analgesia in the emergency department.","authors":"Calvin Hwang, Ben Michaels, Kristen Park, Andrew Dang, Christine Vo, Stephen Lee, Zlatan Coralic","doi":"10.1093/ajhp/zxaf037","DOIUrl":"https://doi.org/10.1093/ajhp/zxaf037","url":null,"abstract":"<p><strong>Disclaimer: </strong>In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.</p><p><strong>Purpose: </strong>We describe the timing of first-dose sedation and analgesia after rapid sequence intubation (RSI) in patients induced with etomidate and paralyzed with rocuronium or succinylcholine.</p><p><strong>Methods: </strong>This was a retrospective study of adult patients undergoing RSI in 3 emergency departments (EDs). We evaluated the time to administration of analgesia and sedation using a Cox proportional hazard model controlling for choice of paralytic, post-RSI hypotension (nadir systolic blood pressure of less than 100 mm Hg in the first hour), bedside presence of an ED pharmacist, and practice site. We also describe the first doses of post-RSI analgesia and sedation.</p><p><strong>Results: </strong>A total of 2,059 adult patients were included in the study, of whom 1,532 received rocuronium and 527 received succinylcholine. The median time to first dose of sedation was 12 minutes (interquartile range [IQR], 7-26 minutes) in patients given rocuronium and 10 minutes (IQR, 6-19 minutes) in those given succinylcholine. The median time to analgesia was 24 minutes (IQR, 10-78 minutes) and 21 minutes (IQR, 10-60 minutes), respectively. Administration of rocuronium was associated with lower rates of sedation (adjusted hazard ratio [aHR], 0.75; 95% confidence interval [CI], 0.67-0.85) and analgesia (aHR, 0.73; 95% CI, 0.62-0.87). Hypotension was also predictive of decreased sedation (aHR, 0.67; 95% CI, 0.54-0.80), while bedside presence of an ED pharmacist was associated with improvement (aHR, 1.14; 95% CI, 1.03-1.27). Overall, the median post-RSI initial propofol infusion rate was low at 20 µg/kg/min (IQR, 10-30 µg/kg/min).</p><p><strong>Conclusion: </strong>Use of rocuronium for RSI was associated with reduced likelihood of timely post-RSI sedation and analgesia. Coupled with low initial sedative dosing, our findings suggest that patients intubated with rocuronium are at increased risk of being awake during paralysis.</p>","PeriodicalId":7577,"journal":{"name":"American Journal of Health-System Pharmacy","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From patient to practitioner: A pharmacist's perspective as a clinical trial participant.","authors":"Shay Roth","doi":"10.1093/ajhp/zxaf039","DOIUrl":"https://doi.org/10.1093/ajhp/zxaf039","url":null,"abstract":"<p><p>In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.</p>","PeriodicalId":7577,"journal":{"name":"American Journal of Health-System Pharmacy","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Crinecerfont.","authors":"","doi":"10.1093/ajhp/zxaf017","DOIUrl":"https://doi.org/10.1093/ajhp/zxaf017","url":null,"abstract":"","PeriodicalId":7577,"journal":{"name":"American Journal of Health-System Pharmacy","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment disparities and health inequities in emergency medicine-A pharmacist perspective.","authors":"Sarah Cummins, Judah Brown, Lance Ray","doi":"10.1093/ajhp/zxaf034","DOIUrl":"https://doi.org/10.1093/ajhp/zxaf034","url":null,"abstract":"<p><p>In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.</p>","PeriodicalId":7577,"journal":{"name":"American Journal of Health-System Pharmacy","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Landiolol Hydrochloride.","authors":"","doi":"10.1093/ajhp/zxaf018","DOIUrl":"https://doi.org/10.1093/ajhp/zxaf018","url":null,"abstract":"","PeriodicalId":7577,"journal":{"name":"American Journal of Health-System Pharmacy","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}